Hospitals can and regularly do perform DNA-based tests on newborns, though the type of testing depends heavily on the circumstances. Nearly every baby born in the United States undergoes a routine newborn screening that involves collecting a small blood sample from the heel, and while this screen has traditionally relied on biochemical assays rather than full DNA analysis, genetic testing technology is increasingly being layered onto hospital-based newborn care. What most parents picture when they hear “DNA test at birth,” however, covers a surprisingly wide range of possibilities, from standard screening panels to rapid whole-genome sequencing for critically ill infants to paternity testing, and each follows very different rules about when it happens, who pays, and whether you have to consent.
The Heel Prick Every Newborn Gets
Within 24 to 48 hours of birth, a nurse will prick your baby’s heel to collect a few drops of blood on a special filter card. This is the standard newborn screening that has been performed in U.S. hospitals since the 1960s, and it checks for a panel of metabolic, endocrine, and blood disorders. The exact number of conditions screened varies by state but typically ranges from about 30 to more than 60. For most of its history, this screening relied on biochemical markers rather than DNA analysis, but that line has blurred. Some states now use DNA-based confirmatory testing for certain conditions flagged by the initial screen, using targeted gene panels designed specifically for newborn screening diseases.1Genetics in Medicine. Development of DNA Confirmatory and High-Risk Diagnostic Testing for Newborns Using Targeted Next-Generation DNA Sequencing
An important detail that surprises many parents: in most states, you are not asked for explicit consent before this blood sample is collected. A survey of newborn screening programs found that roughly three-quarters notify parents but do not request consent, and about one in five programs neither notify parents nor obtain consent before screening.2Pediatrics. Newborn Screening Program Practices in the United States: Notification, Research, and Consent The rationale is that these conditions are treatable if caught early, and delays can cause serious harm. Still, this is a source of ongoing debate, particularly as screening programs expand to include more conditions and more genetic information.
When a Sick Newborn Needs Genetic Answers Fast
The most medically urgent DNA testing in hospitals happens in the neonatal intensive care unit. When a baby is born with unexplained seizures, breathing failure, or unusual physical findings, doctors often need to identify a genetic cause quickly because the diagnosis directly changes treatment. Over the past decade, rapid whole-genome sequencing has moved from a research curiosity to a real clinical tool in these settings. One pioneering study demonstrated that whole-genome sequencing could deliver a diagnosis in about 50 hours, identifying conditions that would have taken weeks or months to pin down through traditional testing.3PubMed Central. Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units
The clinical stakes are real. In one case described in the medical literature, a targeted genetic panel identified two disease-causing variants in a gene related to surfactant production in a newborn who required maximum ventilatory support. The diagnosis gave the family and medical team clarity about prognosis and allowed them to make informed decisions about care, including whether to pursue lung transplant.4PubMed Central. Challenges in the clinical understanding of genetic testing in birth defects and pediatric diseases Without genetic testing, the underlying cause might never have been identified, and treatments would have continued on a trial-and-error basis.
From 2012 to 2021, more than 30 clinical studies documented the usefulness of rapid or ultrarapid whole-genome sequencing in NICUs, showing it can identify disease-causing genetic variants that change how doctors manage the baby’s care, suggest new treatments, and help families understand what to expect.5PubMed Central. The Role of Genome Sequencing in Neonatal Intensive Care Units This kind of testing is increasingly available at major children’s hospitals and academic medical centers, though it is far from universal.
The Cost Question for NICU Genetic Testing
Genetic testing in the NICU is not cheap, and insurance coverage is inconsistent. But the financial picture is more complicated than a simple price tag. A study of more than 1,300 patients in a large NICU found that about 9% received a genetic diagnosis, and those babies had significantly longer stays and higher charges: on average about $599,000 compared with $352,000 for infants without a genetic condition.6The Journal of Pediatrics. High Prevalence of Genetic Diseases and Economic Impact in a Level IV Neonatal Intensive Care Unit The excess charges across all genetically diagnosed patients in that single NICU over two years exceeded $28 million. Early genetic diagnosis can sometimes shorten these stays by ending diagnostic odysseys and directing treatment more efficiently, which is a key part of the argument for making rapid sequencing more widely available.
Whether your insurance covers genetic testing for a newborn depends on the clinical situation. If a doctor orders testing because your baby is critically ill and a genetic diagnosis would change management, insurance is more likely to cover it. Elective or research-based sequencing, on the other hand, is rarely covered. Some families end up paying out of pocket, and costs for clinical whole-genome sequencing can range from a few hundred dollars for targeted panels to several thousand for comprehensive sequencing.
Population-Level Newborn Genomic Screening
Beyond testing sick babies, there is growing momentum to offer genome sequencing to all newborns as a screening tool, not just those who are already showing symptoms. Several large research projects are exploring what happens when you sequence healthy-appearing babies at birth. The BabySeq Project, one of the most prominent of these efforts, has enrolled a diverse group of infants and is evaluating how genome sequencing performs as a population-level screen.7The American Journal of Human Genetics. The BabySeq Project: A clinical trial of genome sequencing in a diverse cohort of infants
Results from a large trial of expanded newborn screening using genome sequencing found that about 3.7% of newborns received a positive screen result. Of those, roughly 80% were confirmed as true positives, and the vast majority of those confirmed findings had not been picked up by traditional newborn screening.8JAMA. Expanded Newborn Screening Using Genome Sequencing for Early Actionable Conditions That means genome sequencing caught conditions that the standard heel-prick panel missed entirely. These were conditions considered medically actionable, meaning there is something doctors can do about them if they know early enough.
This does not mean every hospital will soon be sequencing every newborn. The infrastructure, genetic counseling workforce, and follow-up systems needed to handle population-level genomic screening are still being built. But the technology is clearly feasible and catching real diagnoses, so it is reasonable to expect these programs to expand over the next decade.
Paternity Testing at the Hospital
Many people searching about DNA tests at birth are really asking whether the hospital will perform a paternity test. The short answer: hospitals do not routinely perform paternity tests, and most will not offer one unless there is a specific legal or medical reason. A paternity test is not part of standard newborn care. If you want one done, you typically need to arrange it separately through a testing company or request it through legal channels.
Some hospitals do have programs that facilitate voluntary paternity establishment, particularly for unmarried parents, but these are legal acknowledgment programs rather than DNA tests. The father signs an affidavit of paternity, which establishes legal fatherhood without genetic testing. If there is a dispute or uncertainty, court-ordered paternity testing uses a DNA sample (usually a cheek swab) from the baby, the mother, and the alleged father, and the testing is performed by an accredited laboratory. This can sometimes be arranged while the family is still in the hospital, but it is not something the hospital initiates on its own.
If you are considering a paternity test at birth, the key distinction is between “legal” and “informational” testing. A legal paternity test requires documented chain of custody for the DNA samples, meaning the collection is witnessed and the samples are tracked to prevent tampering. Only results from chain-of-custody testing hold up in court. An informational test, including any home DNA kit you might order, can tell you the answer privately but has no legal standing.
Consent, Privacy, and the Question of Who Decides
Consent for newborn genetic testing operates differently depending on the type of test. As noted earlier, standard newborn screening happens in most states without explicit parental consent. But for any testing beyond the state-mandated panel, including whole-genome sequencing, targeted diagnostic panels, or research studies, hospitals are required to obtain informed consent from the parents.
The consent process for genomic sequencing is more involved than signing a standard hospital form. Parents need to understand what the test can find, what it cannot find, and what might be done with the information. Privacy is a real concern. The federal Genetic Information Nondiscrimination Act, commonly called GINA, prevents health insurance companies from using genetic test results to deny coverage or set premiums, and it prevents employers from using genetic information in hiring or workplace decisions.9Genetics in Medicine. Parental interest in genomic sequencing of newborns: enrollment experience from the BabySeq Project That sounds reassuring, but there are significant gaps. GINA does not cover life insurance, long-term care insurance, or disability insurance. It also does not apply to the military health system or to employers with fewer than 15 employees. Some states have additional protections, but coverage is a patchwork.
These gaps matter, and families know it. In studies offering newborn sequencing, between 40% and 79% of families who declined cited privacy or discrimination concerns as a reason.9Genetics in Medicine. Parental interest in genomic sequencing of newborns: enrollment experience from the BabySeq Project Whether or not those fears are well-calibrated to the current legal landscape, they are widespread and not unreasonable, especially given how quickly genetic data can be repurposed in ways nobody anticipated at the time of collection.
What Happens to Your Baby’s Blood Sample Afterward
After the standard newborn screening is complete, the leftover dried blood spots are stored. How long they are kept and what can be done with them varies dramatically by state. Some states destroy samples within a few months. Others store them indefinitely. These residual blood spots have been used for quality assurance, to develop new screening tests, and in some cases for public health research or even law enforcement purposes, which has generated significant controversy.
Several high-profile legal cases have involved parents who were unaware that their baby’s blood spots had been retained and used for purposes they never consented to. Some states have since updated their policies to require explicit consent for research use of stored samples or to destroy samples after a set period. If this concerns you, it is worth checking your state’s specific policy. You can also ask the hospital or your state’s newborn screening program about opting out of long-term storage, though the availability of that option varies.
The Psychological Side of Learning Your Newborn’s Genetic Information
Getting genetic results about a newborn is not just a medical event; it can reshape how parents relate to their child. Researchers have identified several areas where learning genomic information during the newborn period could affect families, including how vulnerable parents perceive their child to be, how bonding unfolds in the early weeks, and whether parents experience blame toward themselves or each other for passing on a genetic variant.10PubMed Central. Potential Psychosocial Risks of Sequencing Newborns A scoping review of public and parent perspectives found concerns about the psychological weight of learning about untreatable or late-onset conditions, the worry that test results could disrupt early parent-child bonding, and a lack of mental health support for families receiving unexpected findings.11European Journal of Human Genetics. Public and parent perspectives on genomic sequencing in newborn screening: a scoping review
The encouraging news is that actual data from families who went through genomic sequencing of their newborn are more reassuring than these theoretical concerns might suggest. In the BabySeq Project’s randomized trial, families who received genome sequencing results, including those who learned their baby carried a risk for a genetic disease, did not show lasting negative psychological effects compared with families who received only standard screening.12JAMA Pediatrics. Psychosocial Effect of Newborn Genomic Sequencing on Families in the BabySeq Project: A Randomized Clinical Trial That does not mean the experience is stress-free in the moment, but it suggests that with proper counseling and support, most families handle the information without long-term psychological harm.
The Ethics of What to Look For and What to Report
When you sequence a newborn’s entire genome, you inevitably find things you were not looking for. A baby being tested for a metabolic condition might also carry a variant linked to cancer risk in adulthood, or a predisposition to a neurological condition that would not appear for decades. Whether and how to report these incidental findings is one of the thorniest ethical questions in newborn genomics.
Some ethicists argue that researchers and clinicians should design newborn testing to avoid identifying adult-onset genetic variants whenever possible, and that parents should not be offered this information unless it is directly relevant to the child’s current or near-term health.13PubMed Central. Ethical Issues in Newborn Sequencing Research: The Case Study of BabySeq The reasoning is that the child has a right to decide, as an adult, whether they want to know their genetic risk for conditions that will not affect them for decades. Returning that information to parents during the newborn period removes the child’s future autonomy over that decision.
In practice, most clinical programs handle this by using a curated list of genes to report on rather than returning the full genome. The expanded newborn screening trial that found a 3.7% positive rate, for instance, focused specifically on conditions deemed early-actionable, meaning there is a medical intervention available in childhood. This targeted approach avoids the problem of drowning parents in uncertain or unactionable information, though it means some potentially relevant findings go unreported.
Direct-to-Consumer Kits Are Not the Same Thing
Some parents, rather than waiting for the hospital to test, consider ordering a consumer DNA kit for their newborn. The products available from well-known genetic testing companies can provide information about ancestry and certain health traits, but they operate under fundamentally different standards than hospital-based testing. Medical-grade genetic testing labs are certified under CLIA and accredited by CAP, which involve rigorous quality controls. Consumer testing labs may not meet these standards, and even those with FDA approval come with the agency’s own caveat that results should not be used for diagnosis or to guide treatment decisions.14Ambry Genetics Blog. How are Direct-to-Consumer and Medical-Grade Genetic Tests Different?
If you are thinking about genetic testing for a healthy newborn, consumer kits are not a substitute for medical-grade testing. They look at a limited number of genetic markers and lack the clinical interpretation that makes results medically useful. A finding from a consumer test cannot be acted on clinically without being confirmed by a CLIA-certified lab. If you have a specific concern about a genetic condition in your family, talk to your pediatrician or a genetic counselor about ordering appropriate clinical-grade testing.
Equity Gaps in Newborn Genomic Testing
One underappreciated problem with expanding genomic testing to newborns is that the databases used to interpret genetic variants are heavily skewed toward people of European ancestry. When a lab sequences a baby’s DNA and finds an unfamiliar variant, they compare it against databases of known variants to determine whether it is harmless or disease-causing. If the baby comes from an ancestry group that is underrepresented in those databases, there is a higher chance that a variant will be classified as “uncertain,” meaning the lab cannot tell whether it matters or not.15American Journal of Human Genetics. Technical and ethical challenges of gene-variant interpretation in newborn sequencing and pharmacogenomics
This is not a minor technical limitation. An uncertain result is functionally useless for guiding medical decisions, but it still generates anxiety. And the families most likely to receive uncertain results are those from racial and ethnic groups that already face disparities in healthcare access and quality. As newborn genomic screening expands, addressing this database bias is essential to avoid creating a system that works well for some families and poorly for others. Research projects like BabySeq have made diversity in enrollment a priority, but the broader genomic reference databases still have a long way to go.
How DNA Samples Are Actually Collected From Newborns
The physical process of collecting DNA from a newborn is straightforward and minimally invasive. For the standard newborn screen, the heel-prick blood spots provide enough material. For more advanced genomic testing, a small blood draw or sometimes a cheek swab is used. Researchers have also compared DNA quality from different sources, finding that whole blood samples and umbilical cord tissue both provide high-quality DNA suitable for genetic analysis, while the dried blood spots from the heel prick yield less DNA and lower purity, especially after years of storage.16PubMed Central. Isolation of human genomic DNA for genetic analysis from premature neonates: a comparison between newborn dried blood spots, whole blood and umbilical cord tissue
For premature infants in the NICU, where blood draws need to be minimized because the baby is tiny and every milliliter counts, umbilical cord tissue collected at birth can be an alternative DNA source. The quality of DNA from cord tissue matched that of whole blood in genotyping accuracy, making it a practical option when additional blood collection would be medically risky. This means that if genetic testing is anticipated, collecting and preserving a small piece of cord tissue at birth can provide a backup DNA source without requiring additional procedures on the baby later.
Prenatal Testing and How It Connects to What Happens at Birth
Many parents arrive at the hospital having already received some genetic information about their baby through prenatal screening. Noninvasive prenatal testing, which analyzes fragments of fetal DNA circulating in the mother’s blood, can screen for chromosomal conditions like Down syndrome and certain sex chromosome abnormalities during pregnancy. One study of more than 22,000 pregnant women found that this type of screening had a lower false-positive rate than traditional serological screening and could detect sex chromosome abnormalities with positive predictive values ranging from 25% to nearly 86% depending on the specific condition.17Heliyon. The detection efficacy of noninvasive prenatal genetic testing (NIPT) for sex chromosome abnormalities and copy number variation and its differentiation in pregnant women of different ages
Prenatal screening results often shape what happens after birth. If a prenatal screen flagged a possible condition, the medical team may plan confirmatory genetic testing for the baby immediately after delivery. Conversely, a clean prenatal screen does not eliminate the possibility that the baby has a genetic condition, since these screens look at only a subset of possible disorders. The postnatal heel-prick screen and any additional testing ordered at the hospital cover different territory than what was assessed prenatally. Thinking of prenatal and postnatal genetic testing as two complementary layers rather than one replacing the other gives the most accurate picture of what information you actually have about your baby’s genetic health.